Tanaka-Esposito Christine C, Cantillon Daniel J
Division of Electrophysiology, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH.
J Innov Card Rhythm Manag. 2017 May 15;8(5):2717-2723. doi: 10.19102/icrm.2017.080503. eCollection 2017 May.
The leadless cardiac pacemaker was selected to provide empiric pacing support in this patient with a manifest mid-septal accessory pathway who had undergone a previous ablation resulting in injury to the compact atrioventricular node. Although this patient's accessory pathway currently demonstrates stable antegrade conduction properties, diminished and complete resolution of manifest pre-excitation has been well described in patients with Wolff-Parkinson-White syndrome. Because of the patient's young age, an increased risk is present for long-term complications inherent with traditional transvenous pacing. The Nanostim leadless pacemaker (St. Jude Medical, St. Paul, MN, USA) was implanted into the right ventricular myocardium without complication. Pacing performance has remained stable, and the patient has been free of device-related adverse events at 19 months after implant.
对于这位患有明显中隔旁道且曾接受过消融术导致致密房室结损伤的患者,选用无导线心脏起搏器提供经验性起搏支持。尽管该患者目前旁道表现出稳定的前向传导特性,但在 Wolff-Parkinson-White 综合征患者中,明显预激的减轻和完全消失已有详尽描述。鉴于患者年轻,传统经静脉起搏存在的长期并发症风险增加。将 Nanostim 无导线起搏器(美国明尼苏达州圣保罗市圣犹达医疗公司)植入右心室心肌,未发生并发症。起搏性能一直保持稳定,植入后 19 个月患者未出现与器械相关的不良事件。